Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 75 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the firm’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $157.13, for a total value of $11,784.75. Following the transaction, the executive vice president directly owned 20,934 shares of the company’s stock, valued at $3,289,359.42. This represents a 0.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $152.80, for a total transaction of $11,460.00.
• On Tuesday, May 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $147.35, for a total transaction of $11,051.25.

Becton, Dickinson and Company Stock Up 4.6%

NYSE BDX opened at $166.21 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The company’s 50 day simple moving average is $150.67 and its 200 day simple moving average is $164.15. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a market capitalization of $45.80 billion, a P/E ratio of 42.08, a PEG ratio of 11.24 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Analyst Ratings Changes

BDX has been the topic of a number of recent analyst reports. TD Cowen cut their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research report on Monday, May 4th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research note on Monday, July 6th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Finally, Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $180.93.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds and other institutional investors have recently modified their holdings of BDX. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company during the third quarter valued at $25,000. Steph & Co. boosted its position in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the period. SHP Wealth Management acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth about $26,000. Meeder Asset Management Inc. grew its stake in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Finally, Main Street Group LTD acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.